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Abstract: Toxin-antitoxin (TA) systems are small genetic elements found in the majority of
prokaryotes. They encode toxin proteins that interfere with vital cellular functions and are
counteracted by antitoxins. Dependent on the chemical nature of the antitoxins (protein or RNA)
and how they control the activity of the toxin, TA systems are currently divided into six different
types. Genes comprising the TA types I, II and III have been identified in Staphylococcus aureus.
MazF, the toxin of the mazEF locus is a sequence-specific RNase that cleaves a number of
transcripts, including those encoding pathogenicity factors. Two yefM-yoeB paralogs represent
two independent, but auto-regulated TA systems that give rise to ribosome-dependent RNases.
In addition, omega/epsilon/zeta constitutes a tripartite TA system that supposedly plays a role
in the stabilization of resistance factors. The SprA1/SprA1AS and SprF1/SprG1 systems are
post-transcriptionally regulated by RNA antitoxins and encode small membrane damaging proteins.
TA systems controlled by interaction between toxin protein and antitoxin RNA have been identified
in S. aureus in silico, but not yet experimentally proven. A closer inspection of possible links between
TA systems and S. aureus pathophysiology will reveal, if these genetic loci may represent druggable
targets. The modification of a staphylococcal TA toxin to a cyclopeptide antibiotic highlights the
potential of TA systems as rather untapped sources of drug discovery.
Keywords: Staphylococcus aureus; toxin-antitoxin system; plasmid addiction; MazEF; YefM-YoeB;
RNase; SprA1-SprA1AS; SprFG; TenpIN; Omega-Epsilon-Zeta
1. Introduction
Staphylococcus aureus is a ubiquitous Gram positive commensal, colonizing about one third of
the world’s human population. Usually asymptomatic, it is also a notorious etiologic agent of a
multitude of diseases. These range from superficial infections to life-threatening inflammation and
sepsis and are frequently caused by multi-drug resistant strains [1,2]. S. aureus deconvolves its
pathogenicity via numerous virulence factors, including secreted toxins [3]. Commonly, bacterial
toxins are considered to be poisonous compounds associated with pathogens targeting other bacteria
or host cells. Bacterial toxins vary markedly in structure and function, depending in part on whether
they are produced by invasive- or non-invasive pathogens [4].
Notably, however, the term “bacterial toxin” extends beyond factors that primarily harm other
organisms, but also includes proteins which interfere with vital cellular functions of the prokaryotic
cell from which they are encoded. By default, such toxins are negatively controlled by other proteins
or RNAs to form so called toxin-antitoxin (TA) systems [5–7]. TA systems are present also in S. aureus,
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but were originally identified through their role in plasmid maintenance in other bacteria. A brief
history of this field of research and functions of TA systems is given in the following. The episomally
located ccdBA locus encodes the gyrase inhibitor CcdB (the toxin portion of the TA system), which is
held in check by the antitoxin protein CcdA. CcdA is instable and if it cannot be replenished (e.g., after
plasmid loss), cells are eradicated by the action of unleashed CcdB [8,9]. Similarly, faithful partitioning
of plasmids is ensured by the hok-sok TA system identified on the R1 plasmid of Enterobacteriaceae.
In this case, the membrane-targeting Hok toxin is translationally controlled by the small non-coding
RNA antitoxin sok [10].
The plasmid addiction modules ccdBA and hok-sok are paradigms of type II or type I TA systems,
respectively. The activity of type I TA toxins, most of which are small hydrophobic proteins corrupting
cell envelopes, is controlled by an RNA antitoxin that inhibits translation and/or promotes degradation
of toxin mRNA. Cognate toxin and antitoxin loci of type I TA systems are usually overlapping [11–13].
By contrast, in type II TA systems, both toxin and antitoxin are proteins, whose genes are canonically
positioned adjacently within a bi-cistronic operon. Type II TA toxins are generally larger than those
of type I TA systems with modes of action including cleavage of nucleic acids [14], inhibition of
DNA replication [15], inhibition of ribosome assembly [16] and interference with peptidoglycan
synthesis [17]. To date, a total of six different types of TA systems has been proposed, three of which
are characterized by only one verified example each [18–20]. Like in type II systems, the antitoxins of
TA types IV, V and VI are proteins, whereas in type III TA systems, a toxin protein is controlled by
direct interaction with an antitoxin RNA [21]. TA systems are frequently auto-regulated and activated
through alterations in the ratio between antitoxin-bound and free toxin protein. This can be achieved by
a decrease in antitoxin RNA abundance or by proteolytic degradation of protein antitoxins, triggered
by environmental changes or different kinds of stresses. A number of reviews provide a comprehensive
picture of TA systems in general [5–7,22,23] and those regulated by RNAs in particular [11,12].
Sophisticated in silico methods and algorithms have identified TA systems in numerous
prokaryotes [21,24–26], with abundances ranging from nil to several dozen per genome [22]. In contrast
to the systems initially detected on plasmids, many more were found to be encoded chromosomally
with their functions extending beyond plasmid maintenance systems. Instead, TA systems are
most frequently reported in the context of bacterial stress response, programmed cell arrest or cell
death, the formation of drug-tolerant persister cells, pathogenicity, biofilm formation and phage
defense [23,27–34]. Among the staphylococci, TA systems have so far been characterized in the
non-pathogenic S. equorum [35,36] and in S. aureus. For the latter, we here provide an overview on both
experimentally verified and in silico predicted systems, all of which belong to TA types I, II and III.
2. Type I TA Systems
Research on type I TA systems in S. aureus was strongly promoted by investigations of the
enterococcal plasmid pAD1 [37,38], and by the identification of numerous small non-coding RNAs [39–42].
Among a number of postulated TA loci in the S. aureus genome, only two type I TA systems of this
organism have been experimentally characterized to date.
2.1. SprA1/SprA1AS and Further Fst-Like Systems
The TA system par of the Enterococcus faecalis pAD1 vector was the first plasmid maintenance,
or post-segregational killing system to be identified in a Gram positive bacterium [37]. The par locus
encodes two short and convergently transcribed RNAs, designated RNA I and RNA II, the first of
which encodes the peptide Fst which is 33 amino acids in size. The sequence of the shorter RNA II
is largely complementary to RNA I, rendering it capable of inhibiting Fst translation. Weaver and
colleagues demonstrated that Fst of pAD1 affected growth and cell morphology of S. aureus when
inducibly expressed [43]. The authors also identified an Fst-RNA II locus on S. aureus plasmid
VRSAp, which was soon followed by the revelation of further Fst-like TA systems in more than a dozen
S. aureus strains and plasmids [24,44,45]. These systems were found to be episomally or chromosomally
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encoded and associated with theta-replicating plasmids and the staphylococcal pathogenicity island
SaPIbov2. In the course of a whole transcriptome analysis in the N315 strain [39], two of the small
RNAs detected were later verified as antitoxins of type I TA systems (Figure 1A). One of the RNAs
initially designated Teg152 resembles RNA II of the Fst-system. It was later renamed to SprA1AS and
is encoded together with the toxin gene sprA1 in the νΣαβ pathogenicity island of strains including
N315, Newman, NCTC8325 and USA300. As analyzed by the Felden group, expression of both genes
was constitutive with a molar excess of SprA1AS of about 35-90-fold relative to SprA [46]. Both RNAs
fold into structures containing intramolecular double-stranded regions and interact via a specific
duplex formed by non-overlapping 51 domains of each molecule. Toeprinting analysis using purified
S. aureus ribosomes verified translational repression of SprA1 by SprA1AS presumably via prevention
of ribosome loading. An SprA1 encoded peptide termed PepA1 inhibited S. aureus growth in vivo and
this effect could be attenuated upon expression of SprA1AS in trans [46]. In a subsequent study, PepA1
was characterized as a 30 amino acid helical peptide capable of corrupting the S. aureus membrane [47].
Resulting from decreased SprA1AS levels, PepA1 expression is favored in an acidic environment
and during oxidative stress. It has been postulated that the activation of PepA1 by reactive oxygen
species represents a survival strategy of S. aureus after internalization into the phagolysosome of host
immune cells. According to this theory, PepA1 will kill most of the rapidly dividing internalized
bacteria, to allow a minor fraction of slowly diving bacteria to persist. The concomitant damage of
phagolysosomal membranes by PepA1 furthermore favors bacterial escape [47]. As hypothesized,
PepA1 may also play a role in the modulation of iron acquisition by lysis of erythrocytes. Although the
actual function(s) of PepA1 require revelation, SprA1-SprA1AS is currently the most extensively
characterized type I TA system of S. aureus.
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Figure 1. Type I toxin-antitoxin systems in S. aureus (A) The SprA1-SprA1AS toxin-antitoxin system.
Toxin (SprA1) and antitoxin (SprA1AS) RNAs are transcribed from convergent promoters. The toxin
RNA (SprA1) gives rise to a cytotoxic peptide PepA1 that is able to disrupt the host membrane
and erythrocytes. The antitoxin RNA is able to inhibit toxin synthesis by interactions with the
non-overlapping areas; (B) The SprFG1 toxin-antitoxin system. Similar to (A) but from one toxin
RNA two peptides of different lengths (SprG1-short, SprG1-long) are produced. In addition, the
toxin-antitoxin RNA interaction occurs via the overlapping region. Not drawn to scale.
2.2. SprF/SprG
The txpA-ratA family represents another kind of type I TA systems [24], with the TxpA toxin
counter cted by the ratA antitoxin. The first TxpA repres tative as identifi d in the chrom some of
Bacillus s btilis [48] and an in silico analysis identified two poss ble TxpA ho ologs in S. aureus [24]
(Figure 1B). Of these, SprG1, encoded on the mobile genetic element ΦSa3 PI f str in N315, was
experimentall chara terized [49]. The 31 e d of the sprG1 toxin gene is overlapped by t converg ntly
transcribed SprF1 non-coding RNA (Fi ure 1B). Not bly, SprG1 can be either produced from the
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first AUG start codon, yielding a longer, 44 amino acid peptide (SprG1-long) and from an internal
AUG start codon, producing a shorter, 31 residue peptide (SprG1-short) that is the more abundant
form. The RNAs of this TA system were found to be constitutively expressed, with an approximately
12-fold shorter half-life of the SprF1 antitoxin transcript compared to the peptide encoding RNA.
Inducible expression of SprG1 inhibited S. aureus growth, correlated with cell death. Specific duplex
formation with SprF1 negatively regulates SprG1, presumably by RNA degradation. This is in contrast
to the SprA/SprA1AS system, in which inhibition of translation has been proposed to downregulate
SprA1 [11,12,49]. Both SprG1 encoded peptides appear to be secreted pore forming toxins, with the
longer version showing higher lysis activity against human erythrocytes. Together with an observed
activity of the SprG1 peptides against Gram positive and Gram negative bacteria, this finding highlights
that SprF1/SprG1 extends beyond a sensu stricto TA system, since SprG1 encoded peptides fulfill
characteristics of virulence factors [49]. Triggers and functions of the SprF1/SprG1 module are yet to
be identified.
3. Type II TA Systems
Currently three main groups of type II toxin-antitoxin systems have been experimentally verified
in S. aureus, namely MazEF/PemIK, YefM-YoeB (AxeTxe) and Omega-Epsilon-Zeta. All groups
possess proteic toxin and antitoxin components and are found in common S. aureus strains [22,50].
The MazEF/PemIK systems have been studied extensively, whereas considerably less is known about
YefM-YoeB of S. aureus. The tripartite Omega/Epsilon/Zeta TA system has so far not been well
experimentally characterized.
3.1. MazEF and PemIK
MazEF was originally described in E. coli and was the first chromosomal TA system, or “addiction
module” reported [51]. In S. aureus, the toxin component mazF of the mazEF locus was first discovered
and described as an ORF of unknown function during the inspection of the sigB locus that encodes the
alternative sigma factor and stress regulator σB [52]. A later study revealed a relation between mazF
and the pemK toxin gene from E. coli and identified another small ORF, the antitoxin mazE, upstream
of mazF [53]. Based on these results, the prevalence of this TA loci in bacteria was shown shortly
thereafter [54] and it seems likely that the mazEF locus is present in all Staphylococcal species [50,55].
Transcription of mazEF and the genes of the sigB locus (rsbU, V, W and sigB) is coupled, especially
during heat shock [56,57]. The mazEF-rsbUVW-sigB operon (Figure 2A) is proposed to possess at least
three promoters, one upstream of mazEF, one of rsbU and one of rsbV, as well as a Rho-independent
transcriptional terminator downstream of sigB [57,58]. In addition, a weak transcriptional terminator
is predicted downstream of the mazEF genes, permitting transcriptional read-through due to its low
Gibbs free energy [57,59]. This results in several transcripts comprising either only mazEF or, mazEF
and an increasing number of sigB related genes. Unexpectedly, the mazEF promoter is needed for
full activity of the SigB system [57]. In addition, the mazEF promoter is not auto-regulated by its
antitoxin MazE, as in many other TA systems, but instead inhibited by σB. In contrast, both SarA,
a transcriptional regulator and sub-MIC concentrations of erythromycin and tetracycline stimulate
mazEF transcription [57].
Although transcription levels can serve as an indicator, activity of TA system toxin components
are strongly dependent on the levels of toxin and antitoxin proteins in the cell. In type II TA systems,
the unstable antitoxin is continuously degraded by a protease. Upon environmental stresses,
replenishment is insufficient, which shifts toxin-antitoxin ratios and thus unleashes the toxin [5,6].
In S. aureus, MazE possesses a very short half-life of approximately 18 min, which is considerably
shorter compared to its E. coli orthologue [60]. MazE levels stayed steady in a knockout strain of the
ClpP protease and decreased only slowly in a knockout of the chaperone ClpC, indicating that this
proteolytic complex aids in the degradation of MazE [60].
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own operon; (C) The Omega-Epsilon-Zeta system. In contrast to any other type II TA-operons, this is a
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The recently solved structure of MazF from S. aureus revealed a high structural similarity to
its Bacillus subtilis orthologue with a typical MazF/CcdB fold [61–64]. MazF was found to dimerize
to a rigid complex by several inter-molecular contacts. Based upon the NMR and the structural
data, S. aureus MazE antitoxin is thought to bind in the same manner to its MazF toxin as in the
Bacillus orthologue.
Initial investigations on S. aureus MazF were conducted in vitro and in E. coli. A first study already
demonstrated RNase activity [65] and later investigations in icated that UACAU is the preferred
substrate of S. aureus MazF in vivo [55], although others sites were shown to be cleaved in vitro as
well [66,67]. Overexpression of azF in S. aureus has been reported to decrease the amount of CFU,
while cells were reported to be alive in a live-dead staining for at least one hour [68]. It was therefore
proposed that mRNA cleavage by MazF inhibits growth. An investigation of transcript levels in
S. aureus revealed that hla, spa and sigB mRNA amounts were decreased, while levels of sarA, recA
and gyrB remained steady upon induction of azF. In accordance, the protein levels of SigB were
decreased and those of SarA were increased over a time course of 90 minutes [68]. Direct cleavage
of the spa and rsbW transcripts in vivo by MazF at UACAU could be demonstrated but some other
identical pentad sequences remained uncut [55]. It has been proposed that one or more RNA binding
proteins may serve to protect MazF cleavage sites [68] or secondary structure formation of RNAs
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may prevent access of the nuclease. Accordingly, a recent publication highlights the possibility that
some RNAs might be protected by the helicase CshA and this may therefore shape the affected
pool of RNAs [69]. Interestingly, cleavage of UACAU sites can be detected in a WT strain without
overexpression of the toxin or deletion of the antitoxin [55] which suggests that MazF might play a
regulatory role for certain transcripts even under non-stress conditions. Because of the abundance
of UACAU sites in the pathogenicity factor sraP gene [66] and clustering in functional association
networks [70], an involvement of mazEF in pathogenicity has been proposed. However, since the
association of mazEF with sigB is highly conserved also in other Staphylococcus species and since mazEF
is also functional in the non-pathogenic S. equorum [36], it remains to be worked out to what extent
pathogenesis and cell physiology are regulated by mazEF.
The pemIKsa system from S. aureus CH91 is related to the canonical mazEF system, but differs
significantly in its amino acid sequence. It was initially discovered on the plasmid pCH91, but is also
present on other S. aureus plasmids and can be found in the chromosomes of some staphylococcal
species [71]. As expected from a plasmid borne TA system, the pemIKsa locus is able to stabilize
episomal elements as shown in E. coli. Overexpression of the toxin PemKsa leads to a growth defect
in S. aureus, presumably caused by the RNase activity of PemKsa, which can be counteracted by
its antitoxin PemIsa. PemKsa recognizes the target RNA by the sequence UAUU and cleavage
of scpB, adhC, ftsW transcripts was demonstrated in vitro. The degradation of UAUU containing
transcripts could be confirmed in E. coli, where scpB and argR mRNA levels were shown to decrease
upon pemKsa expression. However, when cleavage capability was tested in S. aureus, the previously
cleavable transcript argR was not degraded, whereas scpB and ftsW transcripts could still be cleaved.
This suggests that PemKsa cleavage is differently regulated in S. aureus, similar to what was
demonstrated for the mazEF system [55,68]. Interestingly, the pemIsa gene transcript is not susceptible
to PemKsa, whereas the downstream part containing the pemKsa transcript is degraded. In addition,
in E. coli, the antitoxin PemIsa can be produced even if induced three hours after the onset of toxin
PemKsa expression. It was therefore proposed, that PemKsa production is auto-regulated by the
cleavage of the pemKsa transcript. This would downregulate PemKsa synthesis while continuously
producing the antitoxin PemIsa and therefore restore cell growth [71]. Although a link to pathogenicity
has been hypothesized, it remains unclear what physiological role this system has as a plasmid encoded
element in S. aureus.
3.2. YefM-YoeB (Axe-Txe)
The yefM-yoeB TA systems (also known as axe/txe) are widespread in bacteria and the presence in
the S. aureus genome was first inferred by homology from a plasmid that encoded the orthologous
Francisella phd/yefM TA system [72]. Shortly thereafter, an ortholog was discovered in Enterococcus
which was named axe/txe, and the homology to the S. aureus system was also noted [73]. Owing to the
independent descriptions of the S. aureus orthologs, the TA system is referred to as either YefM-YoeB or
Axe-Txe in literature. To date two paralogous chromosomally encoded systems have been described,
named yefM-yoeB-sa1 (axe-txe1) and yefM-yoeB-sa2 (axe-txe2) [22,57]. Both systems can be found at the
same time in the same strains (Figure 2B).
The antitoxins YefM-sa1 and YefM-sa2 share 25% identity and 47% similarity with each other,
while the toxin components YoeB-sa1 and YoeB-sa2 share 30% identity and 45% similarity [74].
The overexpression of both toxins leads to growth inhibition of E. coli that can be averted by
simultaneously inducing the cognate antitoxin [74]. In contrast to some TA modules in E. coli [75]
the two S. aureus YefM-YoeB paralogs do not cross-talk. i.e., the antitoxin from one system cannot
counteract the toxin from the other system and they also do not transcriptionally regulate each other.
Instead both systems are transcriptionally auto-regulated by their cognate antitoxin [57,74].
It is still unclear, how the activities of the YefM-YoeB systems are modulated. Transcripts and
antitoxin proteins of both systems are present under standard laboratory conditions, but in the presence
of sub-MIC concentrations of the antibiotics erythromycin and tetracycline, their mRNA levels were
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increased [57]. Notably, the YefM-YoeB-sa2 system was detectable on two transcripts instead of only
one. In addition to a smaller, expected transcript, a much longer RNA, comprising a gene annotated as
endo-1,4-glucanase was detected, the abundance of which also increased upon antibiotic stress [57].
Regarding the stability of the antitoxins, it was observed that YefM-sa1 and YefM-sa2 possess
half-lives that are much shorter compared to their E. coli counterparts and MazE [60]. This leaves
room for speculation that these systems might be able to rapidly react to changing environmental
conditions. The degradation of the antitoxin could be pinpointed to ClpP but in contrast to the mazEF
system where ClpC supports degradation of MazE, ClpC is essential for YefM-sa1 and -sa2 proteolysis.
At present it is unknown what triggers the degradation of the antitoxins to unleash the toxin activity
of YoeB.
The YoeB protein from E. coli acts as a ribosome dependent RNase that inhibits growth and
translation [76]. Expression of the S. aureus orthologs YoeB-sa1 and YoeB-sa2 in E. coli also leads
to growth defects and cleavage close to the start codon, however other downstream sites are also
targeted [74]. Despite a recently reported weak ribosome independent cleavage activity of YoeB-sa1
in vitro, the S. aureus orthologues probably exert their functions indeed by cleaving in complex with
the ribosome [77]. Due to the nature of such cleavage it is reasonable to assume, that a large set
of translationally active RNAs are controlled by YoeB. How this supposedly massive shutdown of
translation relates to S. aureus physiology is yet to be determined. In comparison, the RNase MazF
appears to be much more selective due to the recognition of a certain sequence.
3.3. Omega/Epsilon/Zeta
Omega/Epsilon/Zeta constitutes a three component TA system and therefore possesses an
unusual organization (Figure 2C). As in most other systems, the toxin component, here called
Zeta, is inhibited by the antitoxin component Epsilon. The third protein Omega, mediates
regulation of the operon, which is in most other systems achieved by a bifunctional antitoxin,
instead of an additional protein. To our knowledge, there has only been one described instance
of the Omega/Epsilon/Zeta system in S. aureus [78]. The methicillin resistant strain CM05
possesses a chromosomally integrated broad host range plasmid pSM19035 from Streptococcus that
contains the Omega/Epsilon/Zeta toxin-antitoxin system [78,79] by which this genetically unstable
region might be maintained. Functional studies of the Zeta toxin that were done on the related
pneumococcal PezAT system, revealed that the toxin phosphorylates the peptidoglycan precursor
uridine diphosphate-N-acetylglucosamine and therefore inhibits peptidoglycan synthesis leading
to autolysis [17]. A detailed assessment of how this TA system functions in S. aureus and its role is
however still to be made.
4. Type III TA Candidate Systems
In Type III TA systems, antitoxins are encoded by short tandem repeats upstream of the toxin
gene [21]. These antitoxins form pseudoknots that inactivate the cognate toxin via RNA-protein
interaction (Figure 3). The first TA system of this kind, ToxIN, was identified on a plasmid of the
Gram negative plant pathogen Pectobacterium atrosepticum (formerly known as Erwinia carotovora) [80].
The ToxN toxin has endonucleolytic activity and plays a critical role in the induction of cell death
upon phage infection. An in silico study discovered more than 100 type III TA systems throughout the
bacterial domain [21]. According to their primary structures, a total of three type III TA system families
have been categorized and functionally analyzed in E. coli. Representatives of the tenpIN family have
also been detected in S. aureus genomes.
The eponymous member of the tenpIN family was discovered in Photorhabdus luminescens and
termed according to its function as Type III ENdogenous to Photorhabdus Inhibitor/toxiN. tenpIN
loci were identified in three different S. aureus strains, located on plasmids or in the chromosome [21].
The plasmid pPR9 borne tenpN gene encodes a putative protein of 249 amino acids in size, whereas
a 259 residue TenpN homolog may be expressed from the chromosome of S. aureus strain A9754
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and from plasmids including VRSAp, pSK41, pGO1. Studies on type III TA systems in other Gram
positive bacteria have demonstrated anti-phage activity in Lactococcus [81] and functions in plasmid
retention during sporulation of Bacillus thuringiensis [82]. However, these were due to other type III TA
systems, but not members from the tenpIN family. So far no biochemical investigations of the proposed
type III loci of staphylococci have been published and it will be interesting to learn, if they play a
functional role.
Toxins 2016, 8, 140  8 of 13 
investigations  of  the  proposed  type  III  loci  of  staphylococci  have  been  published  and  it will  be 
interesting to learn, if they play a functional role. 
 
Figure 3. Model of  the  type  III  toxin‐antitoxin system TenpIN  in S. aureus. The antitoxin TenpI  is 
predicted to possess three repeats that are proposed to be processed by the toxin TenpN. Presumably 
the processed TenpI RNA  fragments  are  able  to  bind  the  toxin protein  forming  an RNA/protein 
complex. Note  that  this  system  has  not  been  tested  experimentally  in  S.  aureus  and  the  figure 


























What are  the  functions of  the different staphylococcal TA systems? Are one or more of  them  just 
remnants of plasmid  addiction  systems,  recalcitrant  to  evolutionary  eradication  [29], or  are  they 
associated with  so  far  unassigned  phenotypes? Are  additional  staphylococcal  TA  candidate  loci 
proposed by in silico analysis functional? And if so, under which conditions and with which outcome? 
Are there more TA systems hidden in the genomes in S. aureus and other facultatively pathogenic 
Figure 3. Model of the type III toxin-antitoxin system TenpIN in S. aureus. The antitoxin TenpI is
predicted to possess three repeats that are proposed to be processed by the toxin TenpN. Presumably
the processed TenpI RNA fragments are able to bind the toxin protein forming an RNA/protein
complex. Note that this system has not been tested experimentally in S. aureus and the figure
presented here is solely a model based on the predicted chromosomal regions and orthologous systems.
Not drawn to scale.
5. Final Remarks
To date, six types of TA systems have been proposed and representatives of three of them
have been identified in genomes of S. aureus. Regarding the abundance of these systems, there is
considerable strain variation, which may resemble the lifestyles of S. aureus isolates stemming from
different environments [22]. Although the TA systems of S. aureus are relatively well conserved, clear
cut functions or phenotypes have so far been identified only parsimoniously. Several mutant strains
with inactivated TA systems were generated and investigated, particularly pertaining to type II TA
systems which were the first to be characterized in S. aureus. For example, a mazEF deletion strain
was found to be decreased in β-lactam tolerance [44]. It has also been suggested that TA systems
play a role in persister cell formation in S. aureus [68,83–85]. However, in contrast to E. coli, in which
the consecutive deletion of type II TA systems encoding nucleases had resulted in a decrease of drug
tolerant persister levels [86], a tripe knockout S. aureus strain, lacking mazEF and both yefM-yoeB
paralogs did not exhibit this phenotype [87]. This may be due to another kind of persister mechanism
in S. aureus, but it could also reflect that more TA systems remain hidden in the S. aureus genome, yet
to be identified.
Following the notion that TA systems could be exploited for biotechnological purposes or as
targets for novel anti-infectives [88–91], a number of approaches have also been taken in S. aureus.
Bacconi et al. have cloned an epsilon/zeta containing TA system of an E. faecalis plasmid into an S. aureus
vector for enhanced stability during murine infection [92]. Making use of an S. aureus encoded type I
TA toxin, PepA1 (see above) served as a basis for the successful development of a cyclic pseudopeptide
antibiotic, which is active against Gram positive and Gram negative bacteria [93]. The peptide was
optimized to yield a compound with low hemolytic activity and enhanced stability in human serum,
while retaining antimicrobial efficacy.
Future research on staphylococcal TA systems will need to address a number of major questions:
What are the functions of the different staphylococcal TA systems? Are one or more of them just
Toxins 2016, 8, 140 9 of 13
remnants of plasmid addiction systems, recalcitrant to evolutionary eradication [29], or are they
associated with so far unassigned phenotypes? Are additional staphylococcal TA candidate loci
proposed by in silico analysis functional? And if so, under which conditions and with which outcome?
Are there more TA systems hidden in the genomes in S. aureus and other facultatively pathogenic
staphylococci? Particularly TA systems with uncommon types [18–20] or possibly entirely novel modes
of activity control may have gone unnoticed to date.
In the light of an unprecedented need for new antimicrobial compounds [94], TA systems are
considered as an emerging source of both target structures and lead compounds. Future studies will
hopefully shed more light on their functions in S. aureus.
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